Volume 172, Issue 3 pp. 807-810
Correspondence

Pharmacological treatments in pregnant women with psoriasis in the U.S.A.

H.C. Lin

H.C. Lin

Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN, U.S.A

Search for more papers by this author
J.N. Hunnicutt

J.N. Hunnicutt

Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN, U.S.A

Search for more papers by this author
F.A. Moustafa

F.A. Moustafa

Department of Dermatology: Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071 U.S.A

Search for more papers by this author
A.L. Rohr

A.L. Rohr

Department of Dermatology: Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071 U.S.A

Search for more papers by this author
K.E. Huang

Corresponding Author

K.E. Huang

Department of Dermatology: Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071 U.S.A

Correspondence: Karen E. Huang.

E-mail: [email protected]

Search for more papers by this author
R. Balkrishnan

R. Balkrishnan

Department of Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, U.S.A

Search for more papers by this author
S.R. Feldman

S.R. Feldman

Department of Dermatology: Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071 U.S.A

Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071 U.S.A

Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071 U.S.A

Search for more papers by this author
First published: 28 July 2014
Citations: 1
Funding sources: The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P.
Conflicts of interest: S.R.F. is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, BiogenIdec and Bristol Myers Squibb. He has received grants from Galderma, Astellas, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, BiogenIdec, Coria/Valeant, Pharmaderm, Ortho Pharmaceuticals, Aventis Pharmaceuticals, Roche Dermatology, 3M, Bristol Myers Squibb, Stiefel/GlaxoSmithKline, Novartis, Medicis, LEO Pharma, HanAll Pharmaceuticals, Celgene, Basilea and Anacor, and has received stock options from Photomedex. The other authors declare no conflicts of interest.
First page image

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.